Clinical trial Recruiting at 1 site Interventional Ages 65 to 100

PENG nerve block plus dexmedetomidine for hip surgery pain in older adults

Official title: Effect of Perineural Dexmedetomidine as an Adjuvant to Pericapsular Nerve Group Block in Older Adults: A Randomized Controlled Trial

Run by Poznan University of Medical Sciences · NCT07327372 · Data updated 2026-11-12

This will test whether adding a small dose of dexmedetomidine to a PENG nerve block gives longer, better pain relief and reduces opioid need for people 65 and older having hip surgery.

More Hip Osteoarthritis trials

Quick facts

Study typeInterventional
Ages65 Years to 100 Years
SexAll
Enrollment30 (estimated)
SponsorPoznan University of Medical Sciences
Academic / other
Locations1 site (Poznan)
StatusRecruiting
StartedFebruary 6, 2026
Main results expectedJanuary 31, 2027
Study endsFebruary 28, 2027
Registry record updatedMarch 4, 2026
Trial IDNCT07327372 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 65 or older scheduled for elective or emergency hip surgery who can provide informed consent and have no contraindication to a PENG block or the study medications.

Probably not a fit

Patients with allergies to ropivacaine or dexmedetomidine, pre-existing neurologic deficits in the limb, significant coagulopathy, severe hepatic or renal failure, chronic daily opioid use, severe cognitive impairment, or BMI over 40 would not be eligible and are unlikely to receive benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, randomized, controlled trial in older adults undergoing hip surgery comparing a PENG block with ropivacaine alone versus ropivacaine plus low-dose dexmedetomidine. Participants 65 years and older who are eligible for a PENG block will be randomly assigned to one of the two regimens and followed for postoperative pain scores, opioid consumption, motor function, and complications. The trial is single-center at Poznan University of Medical Sciences and uses ultrasound-guided PENG block as part of multimodal perioperative analgesia. Safety monitoring will include assessment for hemodynamic effects, neurologic status, and adverse events related to regional anesthesia and study drugs.

Why it matters

Potential benefit: If successful, adding dexmedetomidine could prolong analgesia, lower opioid use, and help older patients mobilize sooner after hip surgery.

How similar studies have gone: Other regional hip-block techniques and small trials of dexmedetomidine as an adjuvant have shown prolonged analgesia and reduced opioid use, but data specifically on dexmedetomidine added to the PENG block in older adults are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 65 years or older
* Scheduled for elective or emergency hip surgery (e.g., hip fracture fixation or hip arthroplasty)
* ASA physical status I-III
* Ability to communicate pain intensity using the NRS scale
* Written informed consent obtained from the patient or legal representative
* Planned use of PENG block as part of multimodal perioperative analgesia

Exclusion Criteria:

* Patient refusal or inability to provide informed consent
* Allergy, intolerance, or contraindication to any study medication: ropivacaine, dexmedetomidine
* Pre-existing neurological deficit or neuropathy of the affected limb
* Coagulopathy (INR \>1.5, platelets \<100,000/µL) or current therapeutic anticoagulation that contraindicates regional anesthesia
* Infection at or near the injection site
* Severe hepatic or renal impairment
* History of chronic opioid use (daily opioids \>30 days before surgery)
* Cognitive impairment or delirium precluding reliable pain assessment
* BMI \> 40 kg/m² (if you want to exclude for technical difficulty)
* Patients receiving another regional nerve block for hip surgery
* Pregnancy or breastfeeding
* Participation in another interventional clinical trial within 30 days

Where it's running

  • Poznan University of Medical Sciences
    Poznan, Poland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.